AI Engines For more Details: Perplexity Kagi Labs You
Bronchodilation: Aminophylline belongs to a class of medications known as bronchodilators. It works by relaxing the smooth muscles of the airways in the lungs, which helps widen the air passages and improve airflow. This can alleviate symptoms such as wheezing, shortness of breath, and chest tightness associated with asthma and COPD.
Asthma: Aminophylline may be used as an adjunctive treatment for asthma exacerbations, particularly in cases where other bronchodilators, such as beta-agonists or anticholinergics, are ineffective or insufficient. It can also be used for long-term maintenance therapy in some patients with persistent asthma symptoms.
Chronic Obstructive Pulmonary Disease (COPD): Aminophylline may be used in the management of COPD exacerbations, particularly in cases of severe airflow limitation or exacerbations that do not respond adequately to other bronchodilators. It may also be used for maintenance therapy in some patients with stable COPD.
Respiratory Stimulant: In addition to its bronchodilator effects, aminophylline has mild stimulant effects on the respiratory center in the brain, which can help stimulate breathing in certain respiratory conditions, such as central sleep apnea or respiratory depression caused by opioid medications.
Side Effects: Common side effects of aminophylline may include nausea, vomiting, headache, tremors, palpitations, and insomnia. These side effects are usually dose-dependent and may improve over time as the body adjusts to the medication. However, if they persist or become bothersome, it's important to consult a healthcare professional.
Cardiovascular Effects: Aminophylline can have cardiovascular effects, including tachycardia (rapid heart rate), palpitations, and arrhythmias. Patients with pre-existing cardiac conditions, such as heart failure or arrhythmias, should use aminophylline with caution and under the guidance of a healthcare professional.
Drug Interactions: Aminophylline may interact with other medications, including certain antibiotics, antifungals, anticonvulsants, and medications that affect liver enzymes. It's important to inform your healthcare provider about all medications you are taking before starting treatment with aminophylline.
Monitoring: Patients taking aminophylline may require monitoring of blood levels to ensure therapeutic efficacy and to minimize the risk of toxicity. Blood levels of aminophylline should be monitored regularly, especially in patients with renal impairment or hepatic dysfunction.
Pregnancy and Breastfeeding: The safety of aminophylline use during pregnancy or breastfeeding has not been well established. Pregnant or breastfeeding women should consult their healthcare provider before taking aminophylline.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| Taxonomy | Rank | Effect | Citations | Notation |
|---|---|---|---|---|
| Ruminococcus | genus | Decreases | 👪 Source Study | |
| Bacteroides | genus | Decreases | 👪 Source Study | |
| Bilophila | genus | Decreases | 👪 Source Study | High Level Cause Brain Fog(Cognitive impairment) |
| Coprococcus | genus | Decreases | 👪 Source Study | |
| Mediterraneibacter | genus | Decreases | 👪 Source Study | |
| Segatella | genus | Decreases | 👪 Source Study | |
| Enterocloster | genus | Decreases | 👪 Source Study | |
| Bilophila wadsworthia | species | Decreases | 📓 Source Study | |
| Bacteroides ovatus | species | Decreases | 📓 Source Study | |
| Coprococcus comes | species | Decreases | 📓 Source Study | |
| Ruminococcus bromii | species | Decreases | 📓 Source Study | |
| [Ruminococcus] torques | species | Decreases | 📓 Source Study | |
| Enterocloster bolteae | species | Decreases | 📓 Source Study | |
| Segatella copri | species | Decreases | 📓 Source Study | Over 70%ile Indicator of mycotoxin present |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 0.8 | 0.3 | 1.67 |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.3 | 0.8 | -1.67 |
| Allergy to milk products | 0.9 | 0.3 | 2 |
| Alzheimer's disease | 1.4 | 1.5 | -0.07 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.3 | 0.3 | 0 |
| Ankylosing spondylitis | 0.3 | 0.6 | -1 |
| Anorexia Nervosa | 0.3 | 0.6 | -1 |
| Antiphospholipid syndrome (APS) | 0.3 | -0.3 | |
| Asthma | 0.3 | 0.3 | 0 |
| Atherosclerosis | 0.6 | 0.6 | |
| Atrial fibrillation | 0.9 | 0.6 | 0.5 |
| Autism | 1 | 1.2 | -0.2 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.9 | 0.6 | 0.5 |
| Brain Trauma | 0.6 | -0.6 | |
| Carcinoma | 0.9 | 0.6 | 0.5 |
| Celiac Disease | 0.3 | 0.9 | -2 |
| Cerebral Palsy | 0.3 | 0.6 | -1 |
| Chronic Fatigue Syndrome | 1.3 | 1.8 | -0.38 |
| Chronic Kidney Disease | 0.4 | 0.7 | -0.75 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | 0 |
| Chronic Urticaria (Hives) | 0 | 0 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | -0.3 | |
| Cognitive Function | 0.6 | 0.6 | |
| Colorectal Cancer | 0.9 | 0.3 | 2 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.3 | 0.6 | -1 |
| COVID-19 | 1.1 | 1.6 | -0.45 |
| Crohn's Disease | 1.2 | 0.9 | 0.33 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.3 | 0.6 | -1 |
| Depression | 1.2 | 1.2 | 0 |
| Endometriosis | 0.6 | 0.6 | 0 |
| Epilepsy | 0.3 | 0.3 | 0 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.6 | -0.6 | |
| Functional constipation / chronic idiopathic constipation | 1.4 | 1 | 0.4 |
| gallstone disease (gsd) | 0.3 | 0.3 | |
| Generalized anxiety disorder | 0.6 | 0.6 | 0 |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 0.6 | 0.9 | -0.5 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.7 | 0.7 | 0 |
| Heart Failure | 0.9 | 0.3 | 2 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.3 | -0.3 | |
| hyperglycemia | 0.3 | -0.3 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.7 | 1.2 | -0.71 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.6 | 0.5 | 0.2 |
| Inflammatory Bowel Disease | 0.8 | 1.7 | -1.13 |
| Insomnia | 0.6 | 0.6 | 0 |
| Intelligence | 0.6 | 0 | 0 |
| Intracranial aneurysms | 0.6 | 0.3 | 1 |
| Irritable Bowel Syndrome | 0.7 | 1.4 | -1 |
| ischemic stroke | 0.6 | 0.3 | 1 |
| Liver Cirrhosis | 1.2 | 1.2 | 0 |
| Long COVID | 0.6 | 1.4 | -1.33 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.3 | 0.3 | 0 |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0 | 0.6 | 0 |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Menopause | 0.5 | 0.5 | |
| Metabolic Syndrome | 1.7 | 1.2 | 0.42 |
| Mood Disorders | 1.2 | 1.2 | 0 |
| Multiple Sclerosis | 0.6 | 0.9 | -0.5 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| neuropathic pain | 0.3 | -0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 0.9 | 0.22 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 1.3 | 0.9 | 0.44 |
| obsessive-compulsive disorder | 1 | 0.7 | 0.43 |
| Osteoarthritis | 0.3 | 0.6 | -1 |
| Osteoporosis | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 1.2 | 0.9 | 0.33 |
| Polycystic ovary syndrome | 1.1 | 1.1 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.3 | 0.6 | -1 |
| Psoriasis | 0.3 | 0.6 | -1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.4 | 0.6 | 1.33 |
| Rosacea | 0.4 | 0.4 | |
| Schizophrenia | 1.2 | 0.9 | 0.33 |
| scoliosis | 0.3 | 0.6 | -1 |
| Sjögren syndrome | 0 | 0.3 | 0 |
| Sleep Apnea | 0.6 | 0.9 | -0.5 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.6 | -1 |
| Systemic Lupus Erythematosus | 0.9 | 0.3 | 2 |
| Tic Disorder | 0.3 | 0 | 0 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.6 | 0.6 | 1.67 |
| Type 2 Diabetes | 1.2 | 0.9 | 0.33 |
| Ulcerative colitis | 0.3 | 1.7 | -4.67 |
| Unhealthy Ageing | 1 | 0.3 | 2.33 |
| Vitiligo | 0.6 | 0.3 | 1 |
